It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Serological testing is emerging as a powerful tool to progress our understanding of COVID-19 exposure, transmission and immune response. Large-scale testing is limited by the need for in-person blood collection by staff trained in venepuncture, and the limited sensitivity of lateral flow tests. Capillary blood self-sampling and postage to laboratories for analysis could provide a reliable alternative. Two-hundred and nine matched venous and capillary blood samples were obtained from thirty nine participants and analysed using a COVID-19 IgG ELISA to detect antibodies against SARS-CoV-2. Thirty eight out of thirty nine participants were able to self-collect an adequate sample of capillary blood (≥ 50 µl). Using plasma from venous blood collected in lithium heparin as the reference standard, matched capillary blood samples, collected in lithium heparin-treated tubes and on filter paper as dried blood spots, achieved a Cohen’s kappa coefficient of > 0.88 (near-perfect agreement, 95% CI 0.738–1.000). Storage of capillary blood at room temperature for up to 7 days post sampling did not affect concordance. Our results indicate that capillary blood self-sampling is a reliable and feasible alternative to venepuncture for serological assessment in COVID-19.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Liverpool School of Tropical Medicine, Centre for Drugs and Diagnostics, Liverpool, UK (GRID:grid.48004.38) (ISNI:0000 0004 1936 9764)
2 Mologic COVID-19 Diagnostics Development Team, Thurleigh, UK (GRID:grid.48004.38)
3 Liverpool School of Tropical Medicine, Centre for Drugs and Diagnostics, Liverpool, UK (GRID:grid.48004.38) (ISNI:0000 0004 1936 9764); Liverpool University Hospitals NHS Foundation Trust (Member of Liverpool Health Partners), Tropical and Infectious Diseases Unit, Liverpool, UK (GRID:grid.10025.36) (ISNI:0000 0004 1936 8470)
4 St George’s University of London, Centre for Diagnostics and Antimicrobial Resistance, Institute for Infection and Immunity, London, UK (GRID:grid.264200.2) (ISNI:0000 0000 8546 682X)
5 Mologic COVID-19 Diagnostics Development Team, Thurleigh, UK (GRID:grid.264200.2)
6 Liverpool University Hospitals NHS Foundation Trust (Member of Liverpool Health Partners), Tropical and Infectious Diseases Unit, Liverpool, UK (GRID:grid.10025.36) (ISNI:0000 0004 1936 8470); University of Liverpool, Department of Clinical Infection, Microbiology and Immunology, Liverpool, UK (GRID:grid.10025.36) (ISNI:0000 0004 1936 8470)